Mention of valley fever is liable to touch off quizzical looks or bad jokes, but to those who have it or are close to someone with it, it is no laughing matter. Life for Lake Elsinore resident Araceli Jimenez underwent a drastic change after her husband came down with the...
Latest News
Philadelphia, PA – Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, representing more than 30% of all pediatric cases. A pilot study in The Journal of Molecular Diagnostics, published by Elsevier, confirms the feasibility of implementing an RNA sequencing analysis (RNA-Seq) workflow for clinical diagnosis of molecular subtypes...
MEMPHIS, Tenn. – Scientists at St. Jude Children’s Research Hospital described the gene regulatory networks contributing to differences between subtypes of the most common childhood cancer, acute lymphoblastic leukemia (ALL). The work examined chromatin, the packaging that compacts DNA, in a cohort of patient samples six times greater than any...
Nice, France – Roca Therapeutics (Roca), a pioneer in non-invasive, first-in-class therapies for severe ocular diseases, today announces the granting of Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its lead clinical candidate, RCT002, in the treatment of Radiation Maculopathy. This regulatory milestone is the result of Roca’s...
MISSISSAUGA, ON – Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on March 5, 2024, the Institut National d’Excellence en Santé et en Services Sociaux (INESSS) recommended Columvi® (glofitamab for injection) for public reimbursement. This recommendation follows the recent positive recommendation from the Canadian Agency for Drugs and...
The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level of diagnostic precision not possible with traditional manual scoring methods. This Breakthrough Device Designation (BDD) demonstrates Roche’s continued...
Roche Diagnostics today announced the launch of a new tuberculosis test for South Africa. Worldwide, South Africa is one of the countries with the highest prevalence of tuberculosis. The new kit detects different species of Mycobacterium from human sputum samples using the LightCycler® 2.0 Instrument. The diagnosis of tuberculosis in...
Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) presents new data for OCREVUS® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (24-26 September). New data show that treatment...
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed, following two cases of fatal acute liver failure Effective immediately, dosing of non-ambulatory patients, irrespective of age, is paused in the clinical setting; dosing of non-ambulatory patients is discontinued in...
Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the phase III STARGLO study1,2 There is an urgent need for effective, immediately available therapies that are broadly accessible to people with transplant-ineligible R/R DLBCL This first-of-its-kind Columvi combination could...